Brief: Eiger BioPharmaceuticals And AnGes Enter Partnership For Lonafarnib In Japan
10/05/2022 22:30
May 10 (Reuters) - AnGes Inc 4563.T :
* EIGER BIOPHARMACEUTICALS AND ANGES ANNOUNCE EXCLUSIVE
PARTNERSHIP FOR REGULATORY APPROVAL AND COMMERCIALIZATION OF
ZOKINVY® (LONAFARNIB) IN JAPAN
* EIGER BIOPHARMACEUTICALS INC - ANGES IS RESPONSIBLE FOR
OBTAINING AND MAINTAINING REGULATORY APPROVAL FOR ZOKINVY IN
JAPAN
* EIGER BIOPHARMACEUTICALS INC - EIGER WILL RECEIVE UPFRONT
AND
MILESTONE PAYMENTS UP TO $1.5M AS WELL AS EARN REVENUE FROM SALE
OF ZOKINVY TO ANGES
Source text for Eikon: ID:nPn8jNQcqa
Further company coverage: 4563.T
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eiger Biopharmaceuticals
See all newsBrief: Eiger Biopharmaceuticals On Sept 5, Bankruptcy Court Entered Order Confirming Fifth Amended Joint Plan Of Liquidation Of Co & Its Debtor Affiliates
Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar
Brief: Eiger Biopharmaceuticals And Amylyx Entered Into An Asset Purchase Agreement
Eiger BioPharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Eiger BioPharmaceuticals Inc expected to post a loss of $7.50 a share - Earnings Preview